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Background: The 6-minute walk test distance (6MWD) has been shown to be a valid and respon-
sive outcome measure in patients with idiopathic pulmonary fibrosis (IPF). The analyses were
based, however, on a single phase 3 trial and require validation in an independent cohort.
Objective: To confirm the performance characteristics and estimates of minimal clinically
important difference (MCID) of 6MWD in an independent cohort of patients with IPF.
Methods: Patients randomized to placebo in the phase 3 CAPACITY trials who had a baseline
6MWD measurement were included in these analyses. The 6MWD and other functional param-
eters (lung function, dyspnea, and health-related quality of life) were measured at baseline
and 24-week intervals. Validity and responsiveness were examined using Spearman correlation
coefficients. The MCID was estimated using distribution- and anchor-based methods.
Results: The analysis comprised 338 patients. Baseline 6MWD was significantly correlated with
lung function measures, patient-reported outcomes, and quality-of-life measures (validity).
Compared with baseline 6MWD, change in 6MWD (responsiveness) showed stronger correlations
with change in lung function parameters and quality-of-life measures. Dyspnea measured by
the University of California San Diego Shortness of Breath Questionnaire showed the strongest
correlations with 6MWD (baseline: coefficient 0.35; 48-week change: coefficient 0.37; both
p < 0.001). The distribution-based analyses of MCID using standard error of measurement
yielded an MCID of 37 m, and distribution-based analyses by effect size resulted in 29.2 m.
The MCID by anchor-based analysis using criterion referencing (health events of hospitalization
or death) was 21.7 m.
Conclusions: The 6MWD is a valid and responsive clinical endpoint, which provides objective
and clinically meaningful information regarding functional status and near-term prognosis.
These results confirm previous findings in an independent cohort of patients with IPF.
ª 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive,
and irreversible parenchymal lung disease of unknown
cause, which primarily occurs in older individuals [1]. This
disease is characterized by reduced lung volumes and
impaired gas exchange, and is associated with symptoms of
progressive dyspnea, cough, and declining exercise capac-
ity. Although its natural history is quite variable, IPF is
typically associated with a poor prognosis; the estimated
median survival after diagnosis is only 2e5 years [2e4].
The 6-minute walk test (6MWT) is a widely used measure
of exercise tolerance, which displays favorable perfor-
mance characteristics in a variety of cardiac and pulmonary
diseases [5e9]. Several studies have evaluated the prog-
nostic utility of the 6MWT in IPF [10e16]; however, until
recently, studies evaluating the performance characteris-
tics of the 6MWT in IPF were limited by small sample size or
enrollment of narrowly defined patient cohorts [10e12,15].
However, in a recent study of 822 patients from a ran-
domized controlled study evaluating interferon-gamma 1b,
the 6MWT was shown to be a reliable, valid, and responsive
measure of disease status and a predictor of 1-year mor-
tality in patients with IPF [17]. In a subsequent study, the
investigators found that both baseline 6MWT distance
(6MWD) and 24-week change in 6MWD were independent
predictors of near-term mortality in an analysis of 748 pa-
tients with IPF [18].
In addition to test performance characteristics, several
studies have evaluated the minimal clinically importantdifference (MCID) for 6MWD in patients with IPF. The MCID
is the smallest difference in a measure that can be
perceived to be important, whether beneficial or harmful,
and that would lead a clinician to consider a change in a
patient’s therapy. Reported MCID estimates, based on
maximal distance walked in 6 min, ranged between 10 m
and 58 m [14,16,17]. In the largest study to date in patients
with IPF, du Bois et al. reported an estimated MCID of
24e45 m [17]. This finding was consistent with the previ-
ously reported estimates of 29e34 m and 28 m (range,
10.8e58.5 m) [14,16].
The objectives of the present study were to confirm the
test performance characteristics and MCID of the 6MWT in
an independent cohort of patients with IPF and, second-
arily, to confirm that exercise tolerance as measured by the
6MWT is a clinically important endpoint in IPF. This work
has been presented in part at the 2012 international
meeting of the European Respiratory Society [19] and the
2013 international meeting of the American Thoracic Soci-
ety [20].
Materials and methods
Study population
The study population included patients with IPF random-
ized to the placebo arms of the two phase 3 CAPACITY
studies of pirfenidone (ClinicalTrials.gov, numbers
NCT00287729 and NCT00287716) [20]. Patients random-
ized to the pirfenidone arms were not included in the
916 S.D. Nathan et al.present analysis due to the drug’s significant treatment
benefit. Eligibility criteria for the CAPACITY studies were
described previously [21]. Briefly, eligible patients were
aged 40e80 years with a diagnosis of IPF within the pre-
vious 48 months; had no evidence of improvement in
disease severity over the previous year; and had predicted
FVC 50%, hemoglobin-corrected predicted DLCO 35%,
either predicted FVC or predicted DLCO 90%, and a 6MWD
150 m.Study assessments
At screening, oxygen titration was performed to determine
the amount of supplemental oxygen each patient needed to
complete the 6MWT without developing oxygen desatura-
tion (blood oxygen saturation [SpO2] <83%). The oxygen
flow rate required to maintain SpO2 of at least 83% for
10 min at rest was determined at screening (subjects in
whom SpO2 83% was not maintained at rest with oxygen
flow of 6 L/min were not eligible for study participation).
The titration proceeded in increments of 2 L/min, starting
with no supplemental oxygen. This oxygen flow rate was
used as the initial testing rate to determine the lowest
oxygen flow required to maintain SpO2 83% during the
6MWT. Again, the titration was done in increments of 2 L/
min. Subjects who were unable to walk for 6 min or at least
150 m while receiving 6 L/min of oxygen were ineligible for
participation in the study. The flow rate determined from
this titration was applied for all subsequent 6MWTs in the
study.
The 6MWT was administered at baseline and 24-week
intervals until week 72. The test was performed on a flat
surface according to a standardized protocol. Patients were
instructed to walk as far as they could without jogging or
running. They were permitted to slow down or stop to rest,
if needed, and were encouraged to resume walking as soon
as they were able. The 6MWT was stopped if the patient
experienced chest pain, intolerable dyspnea, leg cramps,
diaphoresis, or desaturation <83% [19].
At regular intervals, assessments were made of phys-
iologic function (FVC, hemoglobin-corrected DLCO, and
resting alveolar‒arterial gradient of partial pressure of
oxygen [Aea PO2]), dyspnea (University of California San
Diego Shortness of Breath Questionnaire [UCSD SOBQ]),
and health-related quality of life (HRQOL; St George’s
Respiratory Questionnaire [SGRQ]). The UCSD SOBQ is a
24-item questionnaire that evaluates the severity of
dyspnea during 21 different activities of daily living
associated with varying levels of exertion, and includes 3
additional questions about limitations due to shortness of
breath, fear of harm due to overexertion, and fear of
shortness of breath [22]. Each question is scored from
0 to 5; the total score ranges from 0 to 120, with higher
scores indicating greater shortness of breath. The SGRQ is
a 50-item questionnaire that evaluates the frequency and
severity of respiratory symptoms, activities that are
limited by breathlessness or cause breathlessness, and
the impact of these disturbances on social and psycho-
logical functioning [23]. The total SGRQ score ranges
from 0 to 100, with higher scores indicating worsening
HRQOL.Analyses
The validity of the 6MWT was assessed from the associa-
tion between baseline 6MWD and measures of pulmonary
function, dyspnea, and HRQOL [20]. Test responsiveness
was assessed by the association between the change from
baseline to week 48 in 6MWD and the changes from
baseline to week 48 in FVC, hemoglobin-corrected DLCO,
UCSD SOBQ score, and SGRQ score; the association with
resting Aea PO2 was analyzed on the basis of change to
week 72. In addition, the association between the change
in 6MWD from baseline to week 24 and 1-year risk of
mortality was evaluated. Associations were determined
using Spearman correlation coefficients; the strength of
the correlation was determined based on Cohen’s criteria,
under which an absolute value of a coefficient >0.5 is
indicative of a large correlation, 0.5e0.3 of a moderate
correlation, 0.3e0.1 of a weak correlation, and <0.1 of a
trivial correlation [24]. Associations were also evaluated
through a one-way analysis of covariance by comparing
mean 6MWD values across subgroups presumed to have
different capacities for physical endurance based on each
functional parameter (FVC, hemoglobin-corrected DLCO,
resting Aea PO2, UCSD SOBQ score, and SGRQ score). The
relation between 24-week change in 6MWD and mortality
was evaluated using a Cox proportional hazards model
with baseline 6MWD and change in 6MWD as covariates.
The proportional hazard assumption for change in 6MWD
was evaluated using published methods and was satisfied
[25].
Both distribution- and anchor-based methods were used
to estimate the MCID for the 6MWD. Distribution-based
analyses included standard error of measurement (SEM) and
effect size. To calculate the SEM for the 6MWD, the esti-
mated standard deviation (SD) at baseline was multiplied
by the square root of 1 minus the estimated reliability co-
efficient, with 1 SEM defined to be the MCID [17]. To
calculate the effect size, the difference in 6MWD mean
values at baseline and week 48 was divided by the esti-
mated SD at baseline [19]. Anchor-based analysis used the
criterion-referencing approach to estimate the mean dif-
ference in baseline 6MWD between patients who did and
did not meet the composite endpoint of hospitalization or
death [26,27].
Results
Patient characteristics
In all, 347 patients were randomized to the placebo arms in
the CAPACITY studies, of whom 338 (97.4%) were included
in the present analysis (Table 1). The remaining 9 patients
were excluded owing to missing data for the baseline
6MWT. The study cohort had a mean age of 66.5 years, and
the majority were men (72.5%). The mean baseline 6MWD
was 404.6 m (standard deviation 90.4 m). Mean FVC was
74.7% of predicted, and mean UCSD SOBQ and SGRQ scores
were 33.5 and 36.8, respectively. There was, however,
substantial variation in these measures across the study
cohort. In all, 71 patients (21.0%) were using supplemental
oxygen at baseline [19].
Table 1 Baseline characteristics.
Characteristic Value
Age, y (n Z 338)
Mean (SD) 66.5 (7.6)
Median (IQR) 68.0 (61.0e72.0)
Gender, n (%) (n Z 338)
Men 245 (72.5)
Women 93 (27.5)
6MWD, m (n Z 338)
Mean (SD) 404.6 (90.4)
Median (IQR) 404.5 (353.0e457.0)
FVC, % predicted (n Z 338)
Mean (SD) 74.7 (14.9)
Median (IQR) 72.2 (63.2e84.7)
DLCO, % predicted
a (n Z 336)
Mean (SD) 46.8 (9.8)
Median (IQR) 45.2 (39.2e52.0)
Resting Aea PO2, mm Hg (n Z 333)
Mean (SD) 17.8 (12.6)
Median (IQR) 17.4 (10.6e24.1)
UCSD SOBQ score (n Z 331)
Mean (SD) 33.5 (21.5)
Median (IQR) 30.0 (16.0e49.0)
SGRQ score (n Z 326)
Mean (SD) 36.8 (16.7)
Median (IQR) 36.2 (24.3e46.9)
Smoking status, n (%) (n Z 338)
Never 111 (32.8)
Former 210 (62.1)
Current 17 (5.0)
Supplemental oxygen use, n (%) 71 (21.0)
Aea PO2, alveolar‒arterial gradient of partial pressure of oxy-
gen; DLCO, carbon monoxide diffusion capacity; IQR, inter-
quartile range; SD, standard deviation; SGRQ, St. George’s
Respiratory Questionnaire; UCSD SOBQ, University of California
San Diego Shortness of Breath Questionnaire; 6MWD, 6-minute
walk test distance.
a Average hemoglobin-corrected DLCO.
Table 2 Correlation between 6MWD and other measures:
baseline and 48-week change.
Variable Patients, n Coefficient P value
Baseline
FVC, % predicted 338 0.111 0.041
DLCO, % predicted
a 336 0.212 <0.001
Resting Aea PO2,
mm Hg
333 0.171 0.002
UCSD SOBQ score 331 0.346 <0.001
SGRQ score 326 0.290 <0.001
48-Week change
FVC, % predicted 295 0.289 <0.001
DLCO, % predicted
a 291 0.194 <0.001
Resting Aea PO2,
mm Hgb
260 0.191 0.002
UCSD SOBQ score 274 0.366 <0.001
SGRQ score 271 0.303 <0.001
DLCO, carbon monoxide diffusion capacity; FVC, forced vital
capacity; SGRQ, St. George’s Respiratory Questionnaire; UCSD
SOBQ, University of California San Diego Shortness of Breath
Questionnaire; 6MWD, 6-minute walk test distance.
a Average hemoglobin-corrected DLCO.
b 72-Week change for resting alveolar‒arterial gradient of
partial pressure of oxygen (Aea PO2).
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Correlations between 6MWD and selected measures of
functional status were statistically significant (Table 2).
The strongest correlations with the 6MWD were observed
for dyspnea as measured by UCSD SOBQ score and HRQOL as
measured by SGRQ score (both p < 0.001). Patients in the
highest quintile (ie, best values) of hemoglobin-corrected
DLCO, dyspnea, and HRQOL had a significantly better
6MWD than those in the lowest quintile (ie, poorest values;
all p < 0.001; Fig. 1). There was no significant relationship
between FVC quintiles and 6MWD.
Responsiveness
In comparison with the baseline values, stronger correla-
tions were generally observed between 48-week change in
6MWD and 48-week changes in functional parameters,
including % predicted FVC (p < 0.001), Aea PO2
(pZ 0.002), UCSD SOBQ score (p < 0.001), and SGRQ score(p < 0.001) (Table 2). As with baseline values, the strongest
correlation with 6MWD was observed for the USCD SOBQ
measure of dyspnea. The decrease in 6MWD over 48 weeks
was significantly greater in quintiles with the largest 48-
week decline in functional status than in quintiles with
the smallest decline for every functional measure (FVC,
hemoglobin-corrected DLCO, resting Aea PO2, UCSD SOBQ
score, and SGRQ score) (Fig. 2). Significant decreases in
6MWD were also evident in the quintiles with the second
largest functional declines in several parameters including
FVC % predicted, UCSD SOBQ score, and SGRQ score.
In the Cox proportional hazards model, patients with a
shorter baseline 6MWD tended to have higher mortality risk
(Table 3). Similarly, patients with a >50-m 6MWD decline
over the first 24 weeks tended to have greater 1-year
mortality risk than patients with a 50-m decline (hazard
ratio 2.53; 95% confidence interval 0.94e6.79; p Z 0.066).Minimal clinically important difference
Distribution- and anchor-based analyses of 6MWD yielded
MCID estimates ranging between 21.7 and 37 m (Table 4). In
the distribution-based analyses, the MCID derived from the
estimated standard error of measurement was 37 m (95%
confidence interval 34e40), calculated by multiplying the
estimated standard deviation at baseline by the square root
of 1 minus the estimated reliability coefficient (0.83) [17].
The estimated effect size was 0.32 based on a mean change
from baseline to week 48 of 29.2 m. This effect size is
considered moderate according to Cohen’s criteria [24].
Using the criterion-referencing approach, mean baseline
6MWD was significantly different between patients who met
the composite endpoint of hospitalization or death and
those who did not (p Z 0.047). The corresponding MCID,
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Figure 1 Mean baseline 6-minute walk test distance (6MWD) by quintiles of other measures. Error bars represent standard de-
viation (SD). P values shown are nominal; no multiplicity adjustments have been performed. aAverage hemoglobin-corrected DLCO.
Aea PO2, alveolar‒arterial gradient of partial pressure of oxygen; DLCO, carbon monoxide diffusion capacity; FVC, forced vital
capacity; SGRQ, St. George’s Respiratory Questionnaire; UCSD SOBQ, University of California San Diego Shortness of Breath
Questionnaire.
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patient subsets, was 21.7 m.Discussion
The present analysis, conducted in an independent cohort
of patients with IPF, confirms that 6MWD is a valid and
responsive measure of disease status in patients with mild‒
moderate physical impairment due to IPF [17]. Comparedwith baseline 6MWD, change in 6MWD (responsiveness)
showed stronger correlations with change in lung function
parameters and quality-of-life measures. The estimated
MCID for 6MWD in the present study was 21.7e37 m.
The patients evaluated in the present study had been
allocated to the placebo arms of the CAPACITY trials and
were similar in baseline characteristics to the cohort of the
INSPIRE trial evaluated by du Bois and colleagues [17].
Notably, coefficients characterizing the validity and
responsiveness of the 6MWD were largely similar between
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Figure 2 Mean change in 6-minute walk test distance (6MWD) by quintiles of changes in other measures. Error bars represent
standard deviation (SD). P values shown are nominal; no multiplicity adjustments have been performed. aAverage hemoglobin-
corrected DLCO. Aea PO2, alveolar‒arterial gradient of partial pressure of oxygen; DLCO, carbon monoxide diffusion capacity;
FVC, forced vital capacity; SGRQ, St. George’s Respiratory Questionnaire; UCSD SOBQ, University of California San Diego Shortness
of Breath Questionnaire.
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absolute correlation coefficients reported by du Bois et al.
were larger than those in the present study for FVC %
predicted and Aea PO2. In the 48-week comparison (72
weeks for Aea PO2 in CAPACITY), the present study found
larger correlation coefficients for FVC % predicted,
hemoglobin-corrected DLCO, UCSD SOBQ score, and SGRQ
score; the changes in the latter 2 measures increased the
correlation strength to the next level. The associationsbetween 6MWD and 1-year mortality were also similar be-
tween the 2 independent cohorts: the hazard ratios re-
ported here are similar in magnitude to those observed in
the larger cohort by du Bois and colleagues. Statistical
significance was not achieved for mortality in the present
study, which was likely due to a lack of power.
The estimated MCID for 6MWD in the present study was
21.7e37 m, which is consistent with the range of 24e45 m
estimated in the study by du Bois and colleagues [17].
Table 3 Cox proportional hazards model of 1-year
mortality.
6MWD, m Patient
visits, n
Deaths, n HR (95% CI) P value
Baseline
<250 32 2 2.51
(0.55e11.46)
0.235
250e349 88 4 1.90
(0.60e6.05)
0.279
350
(referent)
404 10 e
24-week change
<e50 125 7 2.53
(0.94e6.79)
0.066
e50
(referent)
399 9 e
CI, confidence interval; HR, hazard ratio; 6MWD, 6-minute walk
test distance.
Table 4 Estimation of minimal clinically important dif-
ference in 6MWD in patients with IPF.
Standard error of measurement
Baselinea ICC SEMb (95% CI)
6MWD at baseline
(n Z 338)
404.6 (90.4) 0.83c 37 (34e40)
Effect size
Baselinea Week 48a Differencea Effect
sized
6MWD at baseline
and week
48 (n Z 296)
410.5
(90.0)
381.3
(120.9)
29.2
(79.6)
0.32
Criterion referencing
Criterion Patients, n Baselinea Differencee P valuef
Hospitalization
No 246 409.2 (91.0) 16.9 (11.0) 0.126
Yes 92 392.3 (88.1)
Death
No 318 406.7 (89.7) 36.0 (20.8) 0.084
Yes 20 370.7 (96.0)
Hospitalization or death
No 244 410.6 (89.7) 21.7 (10.9) 0.047
Yes 94 388.9 (90.6)
CI, confidence interval; ICC, intraclass correlation coefficient;
MCID, minimal clinically important difference; SEM, standard
error of measurement.
a Data presented in meters as mean (standard deviation).
b Calculated for 6MWD by multiplying the estimated standard
deviation at baseline by the square root of 1 minus the esti-
mated reliability coefficient. One SEM was defined to be the
MCID; because the SEM is sample-independent, MCID estimates
based on the SEM are considered bidirectional in nature.
c Based on data from du Bois et al., 2011.
d Calculated as difference in 6-minute walk test distance
(6MWD) from baseline to week 48 divided by estimated standard
deviation at baseline.
e Calculated as difference (standard error) in 6MWD in pa-
tients by hospitalization, death, or a composite of hospitaliza-
tion or death.
f P value from independent samples t-test.
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MCID values in the assessment of individual patients, it has
been suggested that the high end of the range should be
used to assess clinical relevance of changes in individual
patients, whereas the lower limit may be used to assess
changes at the population level [28]. On the basis of this
recommendation, the MCID for 6MWD in individual patients
with IPF is 37e45 m and the MCID for IPF populations is
21.7e24 m.
From a clinical perspective, the 6MWT offers a practical
and safe method for evaluating disease status in patients
with IPF, and serial measurements allow tracking of disease
progression over time. The 6MWT requires no special
equipment or advanced training and can be performed in
all patients with IPF, except the most severely impaired.
Because the 6MWT is self-paced, allowing patients to slow
down or rest when needed, it is reflective of submaximal
exercise capacity. The 6MWT therefore provides a measure
of one’s ability to complete normal activities of daily living.
In the absence of validated and practical clinical in-
struments for measuring dyspnea and HRQOL in patients
with IPF, the 6MWT may serve as a useful benchmark for
assessing the degree to which one’s ability to engage in
activities that affect one’s quality of life may be impaired.
Further, the responsiveness of 6MWD to the effect of
treatment in IPF was indicated by the findings of a recent
phase 3 trial of 555 patients [2]. In that study, pirfenidone
therapy resulted in a significant difference compared with
placebo for the prespecified secondary efficacy endpoints
of change from baseline to week 52 in 6MWD and
progression-free survival, a composite endpoint that
included a 50-m decrease in 6MWD as one indicator of
disease progression. These results coupled with those in the
present study support the use of 6MWD as a clinical trial
endpoint either alone or in the context of a composite.
In addition to its potential utility as a measure of
responsiveness to treatment, the 6MWT has been shown to
be a reliable, valid, and responsive measure of disease
status and a predictor of 1-year mortality in patients with
IPF. Although the present study may have beenunderpowered for examination of relationships between
6MWD and mortality outcomes, the 24-week change in
6MWD did show a predictive trend consistent with the
results of the analyses by du Bois and colleagues [17].
These investigators demonstrated the predictive value of
the 6MWT for mortality risk, including the role of both
baseline and 24-week change in 6MWD as independent
predictors of 1-year all-cause mortality in a multivariate
model [18].
Several study limitations are noteworthy. First, the CA-
PACITY trials enrolled patients with mild‒moderate
impairment in lung function caused by IPF and, conse-
quently, the present results may not be generalizable to
patients with more severe IPF. Second, the analysis
included 338 patients randomized to the placebo arms of
the CAPACITY trials, but formal statistical analyses of the
adequate sample size were not conducted. Although the
6MWT in patients with idiopathic pulmonary fibrosis 921sample size appeared adequate for confirming the validity
and responsiveness of the 6MWT, it may have been insuffi-
cient for relating the 6MWT and change in 6MWD to 1-year
outcomes. Third, several distribution- and anchor-based
methods were used to estimate MCID. Hospitalization and
death were included for purposes of comparison with prior
studies. It was anticipated that the criterion-referencing
approach based on hospitalization and death might over-
estimate MCID. Given that death and hospitalization are
major events, one would expect the MCID for minor events
to be smaller than those values reported (and thus those
reported could be interpreted as “upper bounds”). How-
ever, it appeared that the result was generally consistent
withdand perhaps somewhat lower thandthe value
determined by the distribution-based approach. Lastly,
patients receiving pirfenidone were not included in this
analysis as this pharmacologic intervention has been shown
to slow the rate of decline in the 6MWT. The 6MWT changes
are not necessarily concordant with other potential effects
of the drug, which would therefore have affected our an-
alyses of serial change.
Finally, the 2 independent cohorts from the INSPIRE and
CAPACITY trials were very similar but not identical. For
example, the INSPIRE patients were enrolled at 81 centers
in 7 European countries (Belgium, France, Germany,
Ireland, Italy, Spain, and the United Kingdom), the United
States, and Canada, whereas the CAPACITY patients came
from those countries plus Poland, Switzerland, Mexico, and
Australia. There were also minor differences between the
INSPIRE and CAPACITY trials in their inclusion and exclusion
criteria (for example, a lower inclusion threshold for FVC %
predicted of 55% in INSPIRE and 50% in CAPACITY). However,
we perceive these subtle differences as a strength of our
analysis, as they demonstrate that a particular trial popu-
lation need not be replicated to achieve consistently valid
and reliable results with the 6MWT.
In summary, the present analysis of results from the
placebo arms of 2 large multinational, randomized, phase 3
trials in IPF with similar study designs and populations
provides confirmatory evidence pertaining to the perfor-
mance characteristics of the 6MWT. Specifically, the 6MWD
is a valid and responsive clinical endpoint that provides
objective and clinically meaningful information regarding
the functional status and near-term prognosis of patients
with IPF. Our study further helps to establish this easy-to-
perform test as an important assessment tool in the prac-
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